选择性抗瘤效应和线粒体向ptolide衍生物的较低毒性
Wenlan Xing1, Guoliang Liu1, Yue Zhang1
1Department of Natural Product Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China.
Journal of medicinal chemistry
|January 3, 2024
概括
研究人员开发了一种新型的三类衍生物F9,该衍生物向癌细胞线粒体. 这种有针对性的方法增强了抗瘤活性,并在肺癌模型中显著降低了毒性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 在瘤学瘤学.
背景情况:
- 特里普托利德表现出强大的抗瘤活性,但受到显著毒性的限制.
- 线粒体向策略提供了选择性癌症治疗的潜力,因为瘤细胞中的线粒体膜潜力 (MMP) 较高.
研究的目的:
- 开发使用线粒体向载体的新型三类衍生物来增强选择性抗瘤效应并降低毒性.
- 在肺癌模型中评估这些衍生物的疗效和安全性.
主要方法:
- 使用脂友性酸三和F16.使用triptolide的结构修饰.
- 在实验室中对抗瘤活性,线粒体积累,亡诱导,活性氧物种生成和癌细胞 (NCI-H1975) 和正常细胞 (BEAS-2B) 中的MMP变化的评估.
- 在斑马鱼体内活体毒性评估.
主要成果:
- 含F16的三类衍生物保留了抗瘤活性,克服了抑制平原,并在肺癌中提高了选择性.
- 衍生品F9有效地积聚在癌细胞线粒体中,诱导了亡,增加了活性氧物种,并减少了MMP.
- 与三胺相比,F9在斑马鱼的发育,和肝脏毒性显著降低,对正常细胞没有观察到影响.
结论:
- 针对线粒体的ptolide 修改是一种有希望的策略,可以克服其毒性限制.
- 衍生品F9显示了增强的选择性抗瘤疗效和改善的安全性,为肺癌提供了潜在的治疗候选者.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Electron Transport Chain: Complex I and II
13.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


